Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Cardiovascular Therapeutics · 2024-01 · 2024 (1)
DOI: 10.1155/cdr/5549914 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 26.12.2024. Verfasst von Guiping Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei Province, China. Hauptthemen laut MEDLINE: Hirudins, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Heparin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute coronary syndrome (ACS) is one of the most common leading global causes of mortality, encompassing ST‐segment elevation myocardial infarction (STEMI), non‐ST‐segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Percutaneous coronary intervention (PCI) has become a pivotal therapeutic approach for ACS, underscoring the importance of anticoagulation strategies. Among the commonly employed anticoagulants in PCI, heparin and bivalirudin take precedence, with heparin serving as the archetypal choice. Nevertheless, the determination of an optimal anticoagulation regimen remains a point of contention in contemporary clinical practice. To address the differences in anticoagulants during PCI, we meticulously conducted a literature review through PubMed and Web of Science, employing search terms such as “heparin,” “bivalirudin,” “percutaneous coronary intervention,” and “acute coronary syndrome.” For patients with PIC brought on by STEMI, NSTEMI, and stable or UA pectoris, the review focused on randomized controlled trials to assess and compare the efficacy and safety of heparin and bivalirudin as anticoagulant options. This systematic review is aimed at furnishing valuable insights into the ongoing debate surrounding the choice of anticoagulation regimens in PCI. By scrutinizing clinical evidence derived from relevant trials, we seek to inform and guide healthcare practitioners in making informed decisions based on the unique requirements of patients with various ACS presentations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei Province, China.
- School of Public Health, Wuhan University, Wuhan, Hubei Province, China.
- Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA.
ORCID-Profile: Guiping Wang, Kaijie Qi, Xuyang Li, Shuping Zuo, Ruolin Zhang, Yanan Zhao, Suya Sun, Juanjuan Zhang, Xiaokun Liu
Zitieren
APA
Wang, G., Qi, K., Li, X., Zuo, S., Zhang, R., Zhao, Y., Sun, S., Zhang, J., & Liu, X. (2024). Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article. Cardiovascular Therapeutics, 2024(1). https://doi.org/10.1155/cdr/5549914
Vancouver
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, et al. Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article. Cardiovascular Therapeutics. 2024;2024(1). doi:10.1155/cdr/5549914
BibTeX
@article{Wang2024,
author = {Wang, Guiping and Qi, Kaijie and Li, Xuyang and Zuo, Shuping and Zhang, Ruolin and Zhao, Yanan and Sun, Suya and Zhang, Juanjuan and Liu, Xiaokun},
title = {Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article},
journal = {Cardiovascular Therapeutics},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/cdr/5549914}
}
EUVIMED